| Authors: |
Benedetto SR; Neurocrine Biosciences Inc., San Diego, CA., Ionescu A; Neurocrine Biosciences Inc., San Diego, CA., Ge T; Neurocrine Biosciences Inc., San Diego, CA., Furey M; Neurocrine Biosciences Inc., San Diego, CA., Lin S; Neurocrine Biosciences Inc., San Diego, CA., Jha MK; Department of Psychiatry and Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas, TX., Krystal A; Department of Psychiatry, University of California, San Francisco, San Francisco, CA., Shah AA; Department of Psychiatry, Baylor College of Medicine, Houston, TX., Walling DP; CenExel CNS, Garden Grove, CA., Shah N; Neurocrine Biosciences Inc., San Diego, CA., Rizvi SJ; ASR Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, Canada., Kennedy S; ASR Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, Canada.; Department of Psychiatry, University of Toronto, Toronto, Canada., Laurenza A; Takeda Pharmaceutical Company Limited, Cambridge, MA., Murthy V; Takeda Pharmaceutical Company Limited, Cambridge, MA., Roberts E; Neurocrine Biosciences Inc., San Diego, CA., Singh JB; Neurocrine Biosciences Inc., San Diego, CA. |
